Medicinal Cannabis and CBD in Mental Healthcare

O’Brien, Kylie; Blair, Philip

doi:10.1007/978-3-030-78559-8

Cited by 10 publications

(10 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Neurogenesis is particularly important in specific brain regions, such as the hippocampus, linked to memory and learning. Studies suggest that endocannabinoids can enhance neurogenesis and contribute to the brain's ability to adapt to new information [41]. Dysregulation of the endocannabinoid system has been linked to various neurological disorders, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis.…”

Section: Neuroprotection and Neuropathymentioning

confidence: 99%

The Interplay between 2-Arachidonoylglycerol and Anandamide Amidohydrolase in Neuropathy

Ibrahim,

Ayariga,

et al. 2024

Preprint

View full text Add to dashboard Cite

The endocannabinoid system (ECS) is a complex neuromodulatory network in the human body that have enormous impact in developing the central nervous system, as well as modulates various physiological processes. The ECS is made up of anandamide, 2-arachidonoylglycerol (2-AG), which are responsible for the synthesis and degradation of endocannabinoids, and enzymes such as FAAH and MAGL ensures the precise control over endocannabinoid levels. The ECS relies on CB1 receptors found in the central nervous system (CNS), and CB2 receptors found in the peripheral nervous system and immune cells. Dysregulation of the ECS has been associated with several health conditions, prompting investigations into its association with phytocannabinoids to harness their therapeutic potential. The ECS is intricately linked with the nervous system, and it is known to modulate neuronal activities in the CNS, influencing pain and mood modulation. The ECS is also associated with neuropathies-peripheral nerve damage leading to symptoms such as weakness, numbness and pain as evidenced in diabetic neuropathy, Guillain-Barré Syndrome, carpal tunnel syndrome, peripheral neuropathy, and postherpetic neuralgia. The focus of this review is on the interplay between 2-arachidonoylglycerol and anandamide amidohydrolase in neuropathy, elucidating their roles in pain regulation, inflammation, and specific neuropathies. The knowledge generated is expected to have broad implications, providing comprehensive insights into neuropathic conditions and how to improve on them. Ultimately, this understanding may lead to more effective treatments and improved quality of life for individuals affected by these conditions.

show abstract

Section: Neuroprotection and Neuropathymentioning

confidence: 99%

The Interplay between 2-Arachidonoylglycerol and Anandamide Amidohydrolase in Neuropathy

Ibrahim,

Ayariga,

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…The most commonly reported secondary conditions were: back and/ or neck pain (24.5%), generalised anxiety disorder (18.3%), insomnia (23.4%) and stress (28.4%). It is known that chronic pain, anxiety, depression and insomnia can be comorbid (Arrow et al, 2006;Baglioni et al, 2011;Finan and Smith, 2013;Khurshid, 2018;O'Brien and Blair, 2021;Pollack, 2005;Russo et al, 2007;Taylor et al, 2005;van Mill et al, 2010). For example, compared with the general population, people suffering from chronic pain are up to four times more likely to meet diagnostic criteria for mood and anxiety disorders (Arrow et al, 2006).…”

Section: Baseline Characteristicsmentioning

confidence: 99%

Preliminary findings from project Twenty21 Australia: An observational study of patients prescribed medicinal Cannabis for chronic pain, anxiety, posttraumatic stress disorder and multiple sclerosis

O’Brien

Beilby

Frans

et al. 2023

Drug Science, Policy and Law

Self Cite

View full text Add to dashboard Cite

Background Since medical access to medicinal cannabis (MC) was legalised in Australia in 2016, numbers of people prescribed MC have increased exponentially. There is a need for safety and effectiveness data on the longer-term use of MC in real-world settings. This paper describes the methodology of Project Twenty21 Australia, an observational study that commenced early in 2022 and its preliminary findings. Method This study tests whether medicinal cannabis is effective in four primary conditions: chronic pain, anxiety, posttraumatic stress disorder and multiple sclerosis (MS). Participants are prescribed MC from within a Project Formulary, completing questionnaires at baseline then 3 monthly for up to 12 months. Results Between the start of the study in February and 30 August 2022, 278 participants had been recruited into the study: 50.7% female, 48.2% male and 1.1% non-binary with average age 39.2 years (18–77). Patients reported a low quality of life and high levels of co-morbidity. Three-month data, available for 71 participants, indicate that MC was associated with substantial improvements in self-reported quality of life, general health, mood/depression and sleep with standardised effect size estimates ranging from 0.57 to 0.93. Three adverse reactions were reported. Conclusions This paper describes the protocol used for an observational study conducted in Australia assessing the effectiveness of MC in four main conditions. We have established the feasibility of collecting real-world data on symptoms and quality of life in people receiving treatment with MC. Preliminary evidence suggests that MC may be effective in improving quality of life, general health, mood and sleep.

show abstract

“…The most commonly reported secondary conditions were: back and/or neck pain (28.6%), stress (28.6%) and Generalized Anxiety Disorder (23.2%). This is perhaps not surprising as chronic pain, anxiety, depression and insomnia are often comorbid (Arrow et al 2006;Baglioni et al, 2011;Finan and Smith, 2013;Khurshid, 2018;O'Brien and Blair, 2021;Pollack, 2005;Russo et al, 2007;Taylor et al, 2005;van Mill et al, 2010). Compared with the general population, chronic pain sufferers are up to four times more likely to meet diagnostic criteria for mood and anxiety disorders (Arrow et al 2006).…”

Section: Comorbiditiesmentioning

confidence: 99%

Medicinal cannabis for pain: Real-world data on three-month changes in symptoms and quality of life

O’Brien

Beilby

Frans

et al. 2023

Drug Science, Policy and Law

Self Cite

View full text Add to dashboard Cite

Background Internationally, one of the most common conditions for which people seek medicinal cannabis (MC) is chronic pain. However, relatively little is known about the effectiveness of cannabis for reducing pain in Australia. Medicinal cannabis was made legally available in Australia in 2016. Project Twenty21 Australia is an observational study that follows patients prescribed MC for chronic pain, anxiety, PTSD and multiple sclerosis for up to 12 months. It commenced recruitment in February 2022. This paper describes some preliminary findings for a cohort of patients with chronic pain. Method Participants seeking treatment for chronic pain are prescribed MC from within a Project Formulary, and complete questionnaires at baseline then three monthly for up to 12 months. Pain severity and interference are assessed using the Brief Pain Index while standardised measures of quality of life, mood and sleep quality are also applied. Results By 30 November 2022, 55 participants with chronic pain had completed the first three-month follow-up. Patients reported a low quality of life and high levels of co-morbidity. Three-month data indicate that MC use was associated with significant reductions in self-reported pain intensity and pain interference (Effect sizes = 0.66 [95% CI = 0.34–0.98] and 0.56 [0.24–0.88], respectively). Additionally, there were significant improvements in quality of life, general health, mood/depression and sleep (Effect sizes = 0.53–0.63). One adverse reaction was reported which was mild in nature. Conclusions Preliminary evidence suggests that MC may be effective in reducing both pain severity and pain interference while also improving quality of life, general health, mood and sleep in patients with chronic pain. Increasing uptake of MC coupled with growing evidence of both the effectiveness and safety of these medications indicate a need both to make MC more widely available and to reduce financial costs associated with its use.

show abstract

Medicinal Cannabis and CBD in Mental Healthcare

Cited by 10 publications

References 0 publications

The Interplay between 2-Arachidonoylglycerol and Anandamide Amidohydrolase in Neuropathy

The Interplay between 2-Arachidonoylglycerol and Anandamide Amidohydrolase in Neuropathy

Preliminary findings from project Twenty21 Australia: An observational study of patients prescribed medicinal Cannabis for chronic pain, anxiety, posttraumatic stress disorder and multiple sclerosis

Medicinal cannabis for pain: Real-world data on three-month changes in symptoms and quality of life

Contact Info

Product

Resources

About